



SPECIAL ISSUE ARTICLE

From basic sciences and engineering to epileptology: A translational approach

Elie Bou Assi^{1,2}  | Kaspar Schindler³  | Christophe de Bézenac^{4,5}  |
 Timothy Denison^{6,7} | Sharanya Desai⁸ | Simon S. Keller^{4,5}  | Émile Lemoine^{2,9}  |
 Abbas Rahimi¹⁰ | Mahsa Shoaran¹¹ | Christian Rummel¹²

¹Department of Neuroscience, Université de Montréal, Montréal, Canada

²Centre de Recherche du CHUM (CRCHUM), Montréal, Canada

³Department of Neurology, Inselspital, Sleep-Wake-Epilepsy-Center, Bern University Hospital, Bern University, Bern, Switzerland

⁴Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK

⁵The Walton Centre NHS Foundation Trust, Liverpool, UK

⁶MRC Brain Network Dynamics Unit, University of Oxford, Oxford, UK

⁷Department of Engineering Science, University of Oxford, Oxford, UK

⁸NeuroPace, Inc., Mountain View, California, USA

⁹Institute of Biomedical Engineering, Polytechnique Montréal, Montréal, Canada

¹⁰IBM Research Zurich, Rüschlikon, Switzerland

¹¹Institute of Electrical and Micro Engineering, Neuro-X Institute, EPFL, Lausanne, Switzerland

¹²Support Center for Advanced Neuroimaging (SCAN), University Institute for Diagnostic and Interventional Neuroradiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

Correspondence

Elie Bou Assi, CRCHUM, 900 St-Denis Street, Montreal, QC, Canada, H2X 0A9.
 Email: elie.bou.assi.chum@ssss.gouv.qc.ca

Funding information

Centre de Recherche du CHUM, Grant/Award Number: 51616; Institut de Valorisation des Données, Grant/Award Number: 51627; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Grant/Award Number: 200800 and 204593

Abstract

Collaborative efforts between basic scientists, engineers, and clinicians are enabling translational epileptology. In this article, we summarize the recent advances presented at the *International Conference for Technology and Analysis of Seizures* (ICTALS 2022): (1) novel developments of structural magnetic resonance imaging; (2) latest electroencephalography signal-processing applications; (3) big data for the development of clinical tools; (4) the emerging field of hyperdimensional computing; (5) the new generation of artificial intelligence (AI)-enabled neuroprostheses; and (6) the use of collaborative platforms to facilitate epilepsy research translation. We highlight the promise of AI reported in recent investigations and the need for multicenter data-sharing initiatives.

KEYWORDS

electroencephalography, hyperdimensional computing, intelligent neural prostheses, magnetic resonance imaging, scientific platforms

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.


© 2023 The Authors. *Epilepsia* published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.

1 | INTRODUCTION

Translational medicine is a process-oriented discipline that intends to bring novel discoveries in basic research and industrial products into clinical applications.¹ To facilitate this translation, the interaction between basic scientists, engineers, and clinicians is essential. Over the last two decades, the *International Conference for Technology and Analysis of Seizures* (ICTALS; <http://ictals.org/>) has offered a great medium for sharing and advancing knowledge related to the application of basic sciences and engineering in the context of epilepsy, which in turn has been a catalyzing force for translational epileptology.² This work provides a non-exhaustive summary of recent advances focusing on this translation presented during ICTALS 2022, which took place in Bern, Switzerland (Figure 1). Novel developments of structural magnetic resonance imaging (MRI) processing methods are presented, namely, in the areas of gray matter morphometry and white matter analysis. The latest electroencephalography (EEG) signal-processing applications are also discussed, covering both intracranial and scalp EEG recordings. We then overview current and future devices for epilepsy. More specifically, we describe how combining large volumes of patient data with artificial intelligence (AI)* tools can improve clinical management of epilepsy. Two examples are presented of deep learning (DL)† tools developed to learn patterns from millions of ambulatory intracranial EEG (iEEG) records from thousands of patients with epilepsy (PWE) implanted with a responsive neurostimulation device. We then discuss the emerging field of intelligent neural prostheses including a versatile machine learning (ML)‡-based brain state classifier and closed-loop neurostimulator. In addition, energy-efficient in-memory hyperdimensional computing is explained with applications to wearable devices and epileptic seizure detection. Finally, we discuss how collaborative platforms will play a vital role in propelling the translation of novel neurotechnologies to clinical tools.

FIGURE 1 Overview of recent advances in translational epileptology. EEG, electroencephalography; MRI, magnetic resonance imaging.

Translational Epileptology



Key points

- Advances in magnetic resonance imaging (MRI) and electroencephalography (EEG) processing are catalyzing the development of complementary tools for the diagnosis and management of epilepsy.
- Over the last few years, artificial intelligence (AI) has impacted almost all aspects of epilepsy research discussed in this work.
- Although the use of AI in epileptology is showing promise, larger multicenter databases are required.
- Efforts are being put toward making AI energy efficient for implantable devices including advances in hardware implementation and hyperdimensional computing.
- Scientific platforms allow leveraging of the latent flexibility of digital bioelectronics and are facilitating therapy research.

2 | LATEST MRI DEVELOPMENTS

Advances have been made to improve the analysis of MRI for epileptology. Notably, neural current imaging³ might enable measuring field distortions due to epileptic discharges with high spatial resolution using MRI scanners in the near future. Here we concentrate on recent developments in structural MRI (Figure 2).

2.1 | Gray matter morphometry

Morphometric analysis of brain MRI has a longstanding history in epilepsy (see^{4,5} for reviews). Meanwhile, within the worldwide Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Consortium, an




FIGURE 2 Examples of quantitative gray and white matter analysis of brain magnetic resonance imaging (MRI) used in epilepsy research. Morphometric measures derived from T1-weighted MRI (middle left) used to identify atypical brain features in epilepsy cohorts (bottom left) are shown in the left of the figure, including cortical thickness, curvature, and surface segmentations (surface regions of interest [ROIs]). Examples of white matter measures derived from diffusion-weighted MRI (middle right) used to examine brain network alterations associated with epilepsy (bottom right) can be seen on the right. These include metrics such as fractional anisotropy, whole-brain tractography, tract shape features, and metric variation along tracts.

epilepsy work group has been formed.⁶ It has identified subtle but systematic and widespread regional deviations of gray matter (GM) structure from normality in all epilepsy subtypes, affecting both hemispheres and extending far beyond the suspected pathology.^{7,8}

Although these and earlier findings have undoubtedly contributed significantly to the understanding of disease manifestation and potentially also mechanisms, the opinions on the utility of these groups' findings to support diagnostics in the individual were initially mixed. Specialized voxel-based morphometry (VBM) analyses using T1- and T2-weighted MRI together have been presented already in 2005⁹; however, other researchers had more critical views,⁴ questioning the sensitivity and specificity of VBM to detect alterations beyond visual MRI assessment. In contrast, Thesen et al.¹⁰ have applied surface-based analysis (SBA), finding that it yielded high sensitivities and specificities for the detection of cortical lesions. To support the detection of focal cortical dysplasias, the Multi-centre Epilepsy Lesion Detection (MELD) project has been formed, combining SBA with AI-supported approaches.^{11,12}

Independent of research applications, tools for individualized evaluation of volumes of lobar or sublobar cortical and subcortical GM and comparison with normative data sets have become available as commercial products focusing on epilepsy and/or other neurological disorders. Of interest, despite the availability of Conformité Européenne certificates and/or US Food and Drug Administration (FDA) approvals, technical and specifically clinical validation studies are still very rare.¹³ Goodkin et al.¹⁴ have run a clinical evaluation study of the impact of quantitative reports (QReports) on the assessment of hippocampal sclerosis (HS), finding that they helped users with different levels of expertise to improve both the detection accuracy of HS as well as the inter-rater agreement. Non-commercial approaches to support the assessment of individual patient MRI with QReports have been proposed as well.^{15,16}

During the past 5 years, DL with convolutional neural networks (CNNs) has become the method of choice for MRI segmentation.¹⁷ In the context of brain morphometry, CNNs have been used for high-quality segmentation and parcellation of tissue types and brain regions from unenhanced or contrast-enhanced T1-weighted MRI and subsequent cortical-thickness estimation.^{18,19} Another aspect that might turn out relevant to the application of brain morphometry in epilepsy is the discovery of a universal and biophysically plausible scaling law of cortical folding.²⁰ Motivated by the large degree of covariance among variables of cortical morphometry (specifically cortical thickness, and total and exposed surface area), novel and mutually independent variables have been suggested and applied to epilepsy recently.²¹ These might turn out better suited to differentiate pathological developments than the classic variables.

2.2 | White matter analysis

Epilepsy is an archetypal network disorder. Seizures occur within and propagate across neural networks causing a myriad of stereotypical clinical presentations. White matter (WM) is recognized as a crucial component of epileptogenic networks and neuroimaging connectivity studies are increasingly revealing abnormal structural and functional interactions between networked brain regions in PWE,²² particularly cortical and subcortical hubs that demonstrate high connectivity to other brain regions.²³ Neuromodulation of network hubs²⁴ and WM itself²⁵ may reduce the frequency and severity of seizures. There has, therefore, been increasing applications of neuroimaging approaches to study WM in epilepsy, particularly using diffusion MRI (dMRI). WM abnormalities are being identified increasingly in focal and generalized epilepsy

disorders,²⁶ some of which have a demonstrated histopathological basis.²⁷

Refractory temporal lobe epilepsy (TLE) is the most studied epilepsy disorder using dMRI approaches. Limbic WM alterations are frequently reported,²⁶ and the distribution and extent of limbic WM tract abnormalities may account for neuropsychological impairments seen in patients with TLE²⁸ and may represent an imaging marker of postoperative seizure outcome.²⁹ dMRI WM tractography methods may be incorporated into preoperative evaluation pathways, particularly for the reconstruction of the optic radiations prior to anterior temporal lobectomy³⁰ and of eloquent tracts prior to intracranial tumor surgery.³¹ Despite the potential clinical importance of determining WM tract neuroanatomy and WM microstructural alterations in intractable focal epilepsy, no standardized approach currently exists for the acquisition or analysis of dMRI data for research studies or preoperative planning.

There has been an exponential increase in structural connectomic studies in the epilepsies over the past 10 years with ML/DL techniques becoming more and more important.³² Whole-brain structural networks, as revealed through connectomic analysis, are perturbed in focal²² and generalized³³ epilepsies. Among other applications, there is growing evidence indicating that the preoperative structural connectome is a sensitive marker of postoperative seizure control in patients with TLE.^{32,34}

In order to be incorporated into the clinical environment, WM connectomic approaches require unambiguous and simple-to-interpret measures that are patient-centric and powerfully stratifying.³⁵ Conventional diffusion tensor imaging (DTI) WM tractography is most frequently incorporated into the clinical evaluation of PWE. However, these DTI approaches have fundamental limitations, which has significant implications for accurate WM tractography given that a large proportion of WM voxels contain multiple fiber orientations.³⁶

More sophisticated dMRI approaches increase scan time, which may present a barrier to health care pathway implementation. Still, such approaches like constrained spherical deconvolution,³⁷ neurite orientation dispersion and density imaging,³⁸ diffusional kurtosis imaging (DKI),³⁹ or fiber ball white matter modeling (FBWM)⁴⁰ are being used increasingly to evaluate patients with refractory focal epilepsy.

3 | RECENT ADVANCES IN QUANTITATIVE EEG ANALYSIS

For decades, EEG has been considered as one of the main tools used for the care of PWE.^{41,42} Recent guidelines from

the International Federation of Clinical Neurophysiology (IFCN) have highlighted the need for automating EEG reporting and overcoming technical barriers, which is now possible due to advances in computing capabilities, engineering, and signal-processing techniques.⁴² Quantitative EEG analysis allows the extracting of objective and reproducible information. Significant efforts over the last few decades have resulted in the development and interpretation of a variety of quantitative EEG features (univariate and multivariate; linear and non-linear) such as spectral power, chaoticity, signal complexity, cross-frequency coupling, and connectivity. This section provides a non-exhaustive review of recent advances in quantitative analysis of intracranial and scalp EEG recordings (Figure 3).

3.1 | Intracranial EEG recordings

In a report of the American Epilepsy Society Meeting Epilepsy Specialist Symposium, authors concluded that the use of advanced computational analysis of iEEG recordings may help to better delineate the seizure-onset zone.⁴³ Authors discussed the promise of approaches based on a combination of structural connectivity and computational EEG modeling.⁴³ More recently, subpopulations of spikes were investigated based on features such as spike rate, line length, skewness of the spike distribution, and energy for the prediction of surgical outcomes.^{44,45} In line with these investigations, Conrad et al. explored whether sleep and seizure-related changes in spikes allow for localization of the seizure-onset zone.⁴⁶ Bou Assi et al. explored functional connectivity (in terms of phase-locking value) during interictal spikes and showed a decrease in global connectivity (in the gamma frequency band) time-locked to the spike peak.⁴⁷ Authors reported that functional connectivity was lower within the epileptic focus than outside the focus.

In contrast, Müller et al. explored the correspondence between non-linear excess interrelations (measured in terms of matrices of signal pairs' mutual information) and the occurrence of epileptiform events, and found that non-linear quantitative analysis of iEEG could provide useful information during the planning of TLE surgery.⁴⁸ Lundstrom et al. reported promising performances regarding the use of a novel interictal EEG biomarker based on spectral EEG changes (infraslow, delta, and gamma frequencies) for the prediction of mesial temporal involvement in the seizure-onset zone. Authors highlighted the potential of using this quantitative biomarker along with spikes and high-frequency oscillations to guide surgical resection.⁴⁹ Similarly, Stovall et al. explored whether interictal high-frequency “background” EEG (frequency range: 30–500 Hz) can be used to identify the epileptogenic zone




FIGURE 3 Automated analysis of scalp and intracranial electroencephalography (iEEG) to predict clinical outcomes. (A) The raw EEG is acquired and segmented into shorter epochs. The epoch size relates to the timescale of the neurophysiological process being exploited. (B) A traditional machine-learning (ML) pipeline. The EEG is preprocessed (filtering, artifact correction, channel interpolation). Features are then extracted from the processed signal, such as interictal spike morphology and rate, functional connectivity between brain regions, or power spectral density estimated via time-frequency analysis. The features are used as input to a traditional ML model. (C) A deep learning pipeline. Here, the raw EEG is input into a deep neural network (such as a convolutional neural network in the figure). The important features are then learned by the model instead of required to be pre-specified by the engineer. (D) The ML pipeline is optimized to predict a specific clinical outcome. The final model is usually tested on a new set of EEG recordings, and its predictions are compared to the ground truth to assess the model's performances.

and concluded that the concordance between the rate of high-frequency oscillations and high-frequency “background” EEG features (modeled in terms of a pathology score) was a better biomarker than considering each measure individually.⁵⁰

In line with interictal iEEG investigations, Taylor et al. constructed a map of normative brain dynamics from iEEG recordings of 234 PWE that was recorded distant from their seizure-onset zones, based on relative band power.⁵¹ Authors compared iEEG recordings of 62 PWE to the normative map; they found that in patients with bad postoperative outcomes, non-resected regions were more abnormal than resected ones. In contrast, Smith et al. compared the performance of the epileptogenic index and slow polarizing shift index for the localization of the seizure-onset zone.⁵² Authors found that although indices were significantly higher for contacts within the seizure-onset zone, their performances depended on seizure-onset patterns.

Despite significant efforts for the use of quantitative approaches within the context of neurosurgery, the variability of implantation strategies (electrocorticography [ECoG], stereo-EEG, mixture of both) hinders the translation of these models to a clinical setting. In a recent study, Bernabei et al. found distinct relationships in brain networks derived from stereo-EEG and ECoG.⁵³ Authors proposed methods of correction and highlighted the importance of considering the effects of spatial sampling

when applying computational analyses to localize epileptic networks.⁵³

3.2 | Scalp EEG recordings

Recent investigations explored the use of quantitative scalp EEG analysis to assist the diagnosis of epilepsy, mainly based on the use of ML.^{54–59} For example, SpikeNet, a deep neural network, was trained on a total of 9571 scalp EEG records (with and without spikes) to perform spike detection and showed performances compared to those achieved by fellowship-trained neurophysiology experts.⁵⁴ On the other side, DeepSpike was developed for the detection of epileptiform discharges based on multiple instance object detection and required a relatively low number of labeled training data.⁵⁵ For a review regarding the use of DL for the detection of epileptiform discharges from scalp EEG, readers are referred to Ref.⁵⁹ In line with these investigations, Nadalin et al. (2021) trained a CNN for spike ripple detection based on recordings from a total of 34 subjects.⁶⁰ Matos et al. (2022) proposed a classifier for supporting the diagnosis of epilepsy, based on functional connectivity features of EEG in patients who had a first seizure.⁵⁷ Thangavel et al. (2022) developed a classifier to detect EEG recordings from PWE in the presence or absence of interictal epileptiform discharges.⁵⁸ Inputs to the classifier included patient age and vigilance states

in addition to quantitative EEG features such as univariate temporal measures, connectivity, and graph metrics. The algorithm was tested using a leave-one-subject-out cross-validation.

On the other side, Woldman et al. explored whether dynamic functional brain network properties of interictal scalp EEG, as measured in terms of critical coupling, onset index, and participation index, allows one to determine if seizures appear generalized or focal.⁶¹ More recently, Varatharajah et al. developed a classifier, based on scalp EEG, for the prediction of postoperative seizure freedom in patients who underwent anterior temporal lobectomy. Spectral features were extracted from EEG recordings and used as inputs to a Naïve Bayes classifier.⁶² Abou Jaoude et al. proposed an ML algorithm based on deep neural networks (HEAnet) for the detection of hippocampal epileptiform activity from scalp EEG recordings.⁶³

4 | CURRENT AND FUTURE DEVICES

In addition to developments in signal and image-processing techniques, recent studies have investigated the possibility of integrating novel advances in AI into implantable devices for epilepsy. In the next subsections, we discuss how AI allows learning patterns from big data acquired with the NeuroPace RNS System. We then overview new generations of AI-enhanced neural prostheses as well as in-memory hyperdimensional computing (HDC). This section ends by overviewing how scientific collaborative platforms can facilitate translation.

4.1 | Big data to clinical tools

Clinical epilepsy management has many challenges.⁶⁴ One is the inability to accurately assess patient outcomes to treatments, since patient self-reports of seizure counts are often unreliable.⁶⁵ Another challenge is the lack of a systematic approach for exploring the settings of intervention devices such as neurostimulation.⁶⁶ The recent availability of large ambulatory multi-patient iEEG data sets from FDA-approved neurostimulators capable of recording physiological data sets,^{67,68} and advances made in the domains of ML and DL, have equipped the community with tools necessary for addressing these challenges.⁶⁹ Over 10 million, four-channel ambulatory iEEG records from >4000 patients have been captured from patients implanted with the NeuroPace RNS System. Applying AI techniques capable of learning patterns directly from big data to these iEEG records enabled physicians to more objectively assess patient outcomes and select

neurostimulator settings in a personalized, data-driven manner. Two example AI tools developed with these goals in mind are discussed below.

4.1.1 | Electrocorticography sorter

Hundreds of 90-second iEEG records (aka ECoG) are typically captured from each RNS System patient between clinic visits.⁶⁷ These records provide invaluable insights about the patient's epilepsy status including changes in seizure laterality and changes in the number and types of electrographic seizures. Thus identifying stored iEEG records with electrographic seizure activity is of particular interest to physicians. Manually sorting through the iEEG records to find electrographic seizures can add substantial time to the clinical workflow and may lead to reviewer fatigue and increased human error. To aid the iEEG review process, a DL-based electrographic seizure classifier ("ECoG Sorter") was developed.⁷⁰ Individual channels in 138 000 iEEG records from 113 RNS System patients were manually annotated as electrographic seizures or non-seizures. The labeled data sets were used to train a series of CNN models, yielding a classification accuracy of 95.7% on a held-out test data set.⁷⁰ In addition, the trained model's classification scores agreed with three expert physicians at the same level that the physicians agreed with each other.

4.1.2 | Therapy proposer

When physicians make changes to a patient's neurostimulator settings, the approach to finding the next stimulation parameters is often based on their prior experience with treating similar patients.^{66,71} This approach is inherently biased by the physicians' recent memory and does not leverage the experience gathered by other physicians treating similar patients. A tool that searches through large multi-site and multi-patient data sets to identify similar patients in a systematic approach may increase treatment effectiveness and shorten clinical workflows by reducing the demand on physicians to develop new programming settings for every patient. To this end, a platform was developed for identifying patients with similar iEEG patterns, seizure-onset locations, and lead types.⁷² When therapy suggestions are desired for a new patient, k-nearest neighbor's method can be used to identify iEEG records from previously treated similar patients. The search results can be further filtered to match lead types and seizure-onset location with the new patient. Stimulation parameters that worked in the similar patients are suggested as settings for the new patient.

4.2 | Intelligent neural prostheses

Closed-loop neuromodulation is a promising therapeutic approach for medication-refractory brain disorders and could be a game changer for one third of patients with refractory epilepsy. Deployment of ML algorithms on closed-loop neural interfaces enables the accurate detection of pathological brain states and rapid restoration of lost functions. This new generation of AI-enhanced neural prostheses^{73,74} has recently emerged, allowing precise tracking of neurological and psychiatric symptoms, while relieving latency and security concerns of conventional methods. Epileptic seizure control could greatly benefit from such intelligent closed-loop platforms. To this end, a first-of-its-kind ultra-low-power and high-density neural interface microchip was proposed featuring 256-channel ECoG/local field potentials (LFP) recording, biomarker extraction, ML, and closed-loop stimulation capabilities, all integrated on a single chip with an active area of $\sim 3.5 \text{ mm}^2$.^{75,76}

Existing closed-loop devices suffer from relatively low channel count (4–6 channels) and bulky form factor and rely on simple detection methods such as feature thresholding. These issues were addressed by introducing a versatile closed-loop neuromodulation system-on-chip, the NeuralTree. Although a number of recent neural interfaces have integrated ML algorithms directly on the chip,^{77,78} they are still limited in channel count, energy efficiency, and applicability to multiple brain disorders. The NeuralTree system was proposed to address these limitations. This microchip integrates four modules of 64-channel low-noise time-division multiplexed (TDM) mixed-signal front-ends for high-spatial-resolution neural recording. In order to extend the application of this system to a wide range of brain disorders, a rich feature-extraction engine subsequently computes relevant biomarkers in the spectral, temporal, as well as phase domains (the latter is particularly useful for network-based diseases such as psychiatric and memory disorders).^{79,80}

To enable on-site, real-time detection of the seizure state or other neurological conditions, this system embeds an accurate multi-class probabilistic NeuralTree algorithm with two-layer neural networks implemented in the internal nodes.⁸¹ Network pruning and weight quantization were used to compress the networks, requiring only 2.93 kB of on-chip memory. Circuit-algorithm co-design techniques such as energy-aware regularization⁸⁰ enabled an ultra-low-energy classifier, leveraging high-density (256-Ch.) training and channel-selective (64-Ch.) inference. Overall, the combination of TDM-based sensing array, hardware-efficient biomarker extraction, and low-power ML processor enabled an unprecedented channel density in an area- and power-efficient manner.

In response to NeuralTree's detected events, a 16-channel fully-configurable high-voltage-compliant neurostimulator with passive and active charge balancing (integrated on the same chip) is triggered to suppress seizures and other abnormal activities. The chip consumes $0.227 \mu\text{J}/\text{class}$, significantly better than existing commercial and research-based systems. The classification performance was verified on seizure- and tremor-detection tasks. For example, on epileptic scalp EEG (24 patients, 983 h, 176 seizures, from the CHB-MIT data set) and iEEG (6 patients, 596 h, 49 seizures, from the iEEG.org), the chip achieved 95.6%/94% sensitivity and 96.8%/96.9% specificity. The system was further validated in vivo with a 16-channel, subdural soft micro-electrocorticography array on a rat model of epilepsy. Prominent increases in spectral and temporal biomarkers and cross-channel phase synchronization at the seizure onset were observed.⁷⁶

4.3 | In-memory hyperdimensional computing

During their regular check-ups, PWE often undergo a routine EEG recording, which is then evaluated for decisions on therapy continuation or adjustment. This appointment-based data collection, however, is severely under-sampling the highly dynamical nature of epilepsy.⁸² Implantable or wearable devices monitoring EEG changes and specifically seizure occurrence and timing are desirable but require miniaturized architecture and energy-efficient implementation of continuous signal analysis. This is where new brain-inspired ML approaches may help.

The central idea of HDC⁸³ is to compute with random patterns that are drawn from a very high-dimensional space. This was inspired by psychological models of human analogy processing as well as by biological central nervous systems, where information is often represented by very large spatiotemporal distributions of probabilistic neuronal population firing patterns. A key attribute of HDC is its inherent robustness to the imperfections associated with the computational substrates on which it is implemented.⁸⁴ Failure in a component of hyperdimensional random vectors is “not contagious” to other components and failures in a subset of components are compensated by the holographic representation of memory, meaning that the error-free components can still provide a representation “good enough” for distinction.⁸⁴ HDC is, therefore, particularly amenable to emerging approaches in computing at low signal-to-noise ratio conditions such as implantable or wearable monitoring devices. Examples include non-von Neumann in-memory computing, where the physical attributes of nanoscale memristive devices

can be exploited to perform computation, leading to tremendous energy saving.⁸⁵

A primer on HDC for the iEEG seizure-onset detection is provided in⁸² and an application to real-time hand gesture classification from wearable surface electro-myography was made in.⁸⁶ This technology uses high-dimensional distributed representations and relies on the algebraic properties of its key operations to incorporate the advantages of structured symbolic representations and distributed vector representations. When biosignals are transformed to symbols (e.g., by using local binary patterns), they can be easily combined across many channels and over time by the HDC machinery to learn the event of interest (see⁸⁷ for more details). A number of HDC-based algorithms^{88–91} were developed to operate with iEEG. One HDC algorithm quickly learns from few seizure examples⁸⁸ and generalizes well for unseen seizures, even without any false alarms on long-term iEEG data sets.⁸⁹ Furthermore, HDC leads to transparent (explainable) models that can be interpreted, for example, to automatically identify ictogenic brain regions,⁹⁰ ultimately enabling post-translational support for clinical decision-making.

In all these cases, the HDC algorithms operated directly with symbols or extracted features. To enable operation with raw data, it has recently been proposed to combine deep neural networks with the machinery of HDC.⁹² As a result, this new combination allows rapid learning from a few examples without having the domain expert knowledge about the input modality, leading to state-of-the-art performance in few-shot learning.⁹²

4.4 | Collaborative platforms for translation

The total economic cost of neurological disorders exceeds hundreds of billions of dollars worldwide per annum, yet pharmaceutical companies continue to cut investment.^{93–96} As discussed previously, the emerging field of bioelectronics suggests a novel alternative to pharmaceutical intervention by using electronic hardware to intelligently sense and stimulate the nervous system.^{97,98} In addition, bioelectronic systems might be used to optimize pharmaceutical doses by providing unique access to brain network dynamics, and how they respond to interventions.

Bioelectronic systems raise several challenges and opportunities when bridging the translational continuum. The considerations are multi-disciplinary and encompass basic neuroscience, regulated technology, and health care economics. Satisfying multiple demands can create significant hurdles to translation, especially when large

investments over extended timeframes are required to develop the therapy.

These multiple constraints motivate new innovation models that leverage the unique capabilities of electronic platforms. For example, the flexibility of bioelectronic systems allows for the addition of implantable scientific instruments into established devices that enable novel clinical neuroscience while providing a baseline of therapy.⁹⁹ The resulting scientific discoveries can then be applied to prototype new therapies. Successful prototypes are then locked into place with digital upgrades and become the next generation's established system.^{100,101}

Implantable devices that serve epileptology provide illustrative examples of the scientific platform and innovation framework in practice. For example, the NeuroPace RNS system was originally designed to treat medial TLE. But with the surgical procedure established, and the flexibility of the platform accessible to researchers, the device has been used to explore novel treatments including mood disorders,¹⁰² Tourette syndrome,¹⁰³ and eating disorders.¹⁰⁴ In addition, the novel data recording has enabled new insights into both circadian and multi-day rhythmicity in seizure patterns,¹⁰⁵ and the response of the brain networks to anti-convulsants. Similar insights are being gained with deep-brain stimulation systems. The Activa PC+S¹⁰⁶ and Summit RC+S¹⁰⁷ investigational systems are examples where scientific instrumentation was embedded within established commercial devices. These instrumented stimulators were used in the National Institutes of Health (NIH) BRAIN initiative to explore advanced therapies for movement disorders,^{108,109} epilepsy,¹¹⁰ and brain-machine interfacing.¹¹¹ The capacity to gather extended data sets in home environments further advances our understanding of neural states, including sleep, and disease processes.¹¹²

The attractiveness of public-private collaboration is also advancing new models for collaboration. For example, the “Picostim-DyNeuMo,” is a collaborative, investigational research tool co-developed by industry (Bioinduction Ltd, Finetech Medical Ltd) and academics.^{113,114} The Picostim-DyNeuMo is targeting first-in-human clinical studies exploring challenging neurological disorders such as Lennox-Gastaut epilepsy, chronic pain, and disorders of consciousness. Finally, the generality of the bioelectronic platform approach is further reinforced with examples including spinal cord stimulation, and diseases that extend into the peripheral nervous system including spinal cord injury and blood pressure management.

However, platforms are not without their limitations and trade-offs. Concerns include limited degrees of freedom for highly novel approaches (e.g., large channel count designs, or many leads placed in the brain). In addition, novel research systems that are not commercially supported lead to the potential risk of patient abandonment.

The use of novel systems requires careful consideration of equipoise by the clinical investigator, the identification of a long-term care pathway, and transparent ethical disclosures in patient consent.^{115,116}

5 | OUTLOOK

This work provides a non-exhaustive overview of recent translational applications of basic sciences and engineering to epileptology presented during ICTALS 2022. We argue that novel advances in MRI and EEG processing in line with the availability of large ambulatory iEEG data sets can lead to the development of complementary tools for the diagnosis and management of epilepsy. In parallel, special efforts are undertaken to make AI energy efficient for implantable medical devices, including advances in hardware implementation and usage of paradigms novel to the field, like HDC. Novel generations of AI-enhanced neuroprostheses are emerging, which feature rich biomarker extraction as well as improved channel count, per channel area, and energy efficiency. Furthermore, the development of scientific platforms that leverage the latent flexibility of digital electronics is helping catalyze therapy research. By spreading the development costs across multiple disease states and establishing an ecosystem for device implantation and research best practices, the incremental barriers for translational research can be lowered. Ultimately, the success of this strategy will be determined by improved access to novel therapies.

Indeed, the last few years have been marked by advances in AI, which are impacting almost all aspects of epilepsy research discussed herein. There is great promise for the use of AI in epileptology, given that multimodal data are gathered as part of clinical investigations. Nevertheless, databases with large sample sizes are required. Great initiatives have been undertaken to share MRI and EEG recordings and have contributed significantly to advances in the field.

However, multicenter initiatives are required to provide standardized data acquired in different settings along with accompanying annotations and clinical information. In line with the need for multicenter data sets, in a recent editorial, Litt et al. highlighted the need for an epilepsy data sharing ecosystem and the importance of sharing algorithms as well as a lean infrastructure for benchmarking algorithms.¹¹⁷ Such initiatives will allow the testing of algorithms on independent data sets and evaluating models' out of distribution generalization. Indeed, current ML evaluations are based mostly on the assumptions that data in the training and testing sets are independent and identically distributed. However, this assumption might not always be satisfied, particularly in epileptology, where

data is acquired using a variety of devices, settings, people, and time intervals, creating a domain shift between source and target distributions.

In addition, our review shows a progressive transition from traditional AI and ML investigations to the use of DL also in epileptology. Indeed, earlier AI approaches used engineered features, particularly in the field of EEG. In contrast, DL creates a mapping from raw EEG and MRI data to target outputs and does not require feature engineering. Instead, features suitable for the problem domain are generated by the algorithms. Although recent investigations have reported promising performances and such approaches could be beneficial for epileptology, the training of DL models usually requires large amounts of data, and generated features as well as decisions could be sometimes difficult to interpret. Given that translation requires an interdisciplinary understanding, interpretability should be considered in the design and validation of novel algorithms.

Over the last two decades, the ICTALS community has demonstrated the importance of collaboration between basic scientists, engineers, and clinicians for the translation of novel discoveries in basic research and industrial developments to epileptology. We believe that the latest advances in AI combined with interdisciplinary expert knowledge will open the door to novel diagnostic and treatment avenues for people with epilepsy.

ACKNOWLEDGMENTS

We acknowledge the generous sponsorship through unrestricted educational donations for the ICTALS 2022 conference in Bern from the University of Bern, the Inselspital, University Hospital Bern, the Alliance for Epilepsy Research, the Swiss National Science Foundation (SNF), UCB, FHC, the Wyss Center for bio- and neuro-engineering, the American Epilepsy Society (AES), the CURE epilepsy Foundation, Ripple neuro, Sintetica, DIXI medical, UNEEG medical, and NeuroPace. A.R. and K.S. are thankful for support by SNF, grant 200800. C.R. acknowledges SNF support via grant 204593. E.B.A. acknowledges financial support from the Institute for Data Valorization (IVADO, 51627) and the University of Montreal Hospital Research Center (CRCHUM, 51616).

CONFLICT OF INTEREST STATEMENT

Elie Bou Assi, Kaspar Schindler, Christophe de Bézenac, Simon S. Keller, Émile Lemoine, Abbas Rahimi, Mahsa Shoaran, and Christian Rummel have no conflict of interest to disclose. Timothy Denison has stock ownership in Bioinduction, Amber Therapeutics, and MINT Neurotechnology. Sharanya Arcot Desai is an employee of NeuroPace, (Mountain View, CA). We confirm that we have read the Journal's position on issues involved in

ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Elie Bou Assi  <https://orcid.org/0000-0001-8248-2565>

Kaspar Schindler  <https://orcid.org/0000-0002-2387-7767>

Christophe de Bézenac  <https://orcid.org/0000-0002-2433-9776>

Simon S. Keller  <https://orcid.org/0000-0001-5247-9795>

Émile Lemoine  <https://orcid.org/0000-0002-8977-3186>

ENDNOTES

* Artificial Intelligence (AI) refers to the use of computer science and data sets for the development of automated algorithms for tasks that are usually associated with human intelligence. Examples include abstraction and generalization or improving after exposure to more data.

† Deep Learning (DL) is a subset of machine learning that entails the use of artificial neural networks composed of multiple (deep) layers.

‡ Machine Learning (ML) is a subset of artificial intelligence that involves training algorithms without explicit instructions.

REFERENCES

1. Frey FJ. Swiss institute for translational and entrepreneurial medicine (sitem-insel). Clin Transl Neurosci. 2017;1(1):4. <https://doi.org/10.1177/2514183x17714101>
2. Kuhlmann L, Lehnertz K, Richardson MP, Schelter B, Zaveri HP. Seizure prediction — ready for a new era. Nat Rev Neurol. 2018;14(10):618–30.
3. Capigliani M, Turco F, Wiest R, Kiefer C. Analysis of the robustness and dynamics of spin-locking preparations for the detection of oscillatory magnetic fields. Sci Rep. 2022;12(1):16965.
4. Keller SS, Roberts N. Voxel-based morphometry of temporal lobe epilepsy: an introduction and review of the literature. Epilepsia. 2008;49(5):741–57.
5. Martin P, Bender B, Focke NK. Post-processing of structural MRI for individualized diagnostics. Quant Imaging Med Surg. 2015;5(2):188–203.
6. Sisodiya SM, Whelan CD, Hatton SN, Huynh K, Altmann A, Ryten M, et al. The ENIGMA-epilepsy working group: mapping disease from large data sets. Hum Brain Mapp. 2020;43(1):113–28.
7. Whelan CD, Altmann A, Botía JA, Jahanshad N, Hibar DP, Absil J, et al. Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study. Brain. 2018;141(2):391–408.
8. Larivière S, Rodríguez-Cruces R, Royer J, Caligiuri ME, Gambardella A, Concha L, et al. Network-based atrophy modeling in the common epilepsies: a worldwide ENIGMA study. Sci Adv. 2020;6(47):eabc6457.
9. Huppertz HJ, Grimm C, Fauser S, Kassubek J, Mader I, Hochmuth A, et al. Enhanced visualization of blurred gray-white matter junctions in focal cortical dysplasia by voxel-based 3D MRI analysis. Epilepsy Res. 2005;67(1–2):35–50.
10. Thesen T, Quinn BT, Carlson C, Devinsky O, DuBois J, McDonald CR, et al. Detection of epileptogenic cortical malformations with surface-based MRI morphometry. PLoS ONE. 2011;6(2):e16430.
11. Wagstyl K, Whitaker K, Raznahan A, Seidlitz J, Vértes PE, Foldes S, et al. Atlas of lesion locations and postsurgical seizure freedom in focal cortical dysplasia: a MELD study. Epilepsia. 2022;63(1):61–74.
12. Spitzer H, Ripart M, Whitaker K, D'Arco F, Mankad K, Chen AA, et al. Interpretable surface-based detection of focal cortical dysplasias: a multi-Centre epilepsy lesion detection study. Brain. 2022;145(11):3859–71.
13. Pemberton HG, Zaki LAM, Goodkin O, Das RK, Steketee RME, Barkhof F, et al. Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis—a systematic review. Neuroradiology. 2021;63(11):1773–89.
14. Goodkin O, Pemberton HG, Vos SB, Prados F, Das RK, Moggridge J, et al. Clinical evaluation of automated quantitative MRI reports for assessment of hippocampal sclerosis. Eur Radiol. 2021;31(1):34–44.
15. Rummel C, Slavova N, Seiler A, Abela E, Hauf M, Burren Y, et al. Personalized structural image analysis in patients with temporal lobe epilepsy. Sci Rep. 2017;7(1):10883.
16. Rummel C, Aschwanden F, McKinley R, Wagner F, Salmen A, Chan A, et al. A fully automated pipeline for normative atrophy in patients with neurodegenerative disease. Front Neurol [Internet]. 2018;8:727.
17. Yao AD, Cheng DL, Pan I, Kitamura F. Deep learning in neuroradiology: a systematic review of current algorithms and approaches for the new wave of imaging technology. Radiol Artif Intell. 2020;2(2):e190026.
18. Rebsamen M, Rummel C, Reyes M, Wiest R, McKinley R. Direct cortical thickness estimation using deep learning-based anatomy segmentation and cortex parcellation. Hum Brain Mapp. 2020;41(17):4804–14.
19. Rebsamen M, McKinley R, Radojewski P, Pistor M, Friedli C, Hoepner R, et al. Reliable brain morphometry from contrast-enhanced T1w-MRI in patients with multiple sclerosis. Hum Brain Mapp. 2023;44(3):970–9.
20. Mota B, Herculano-Houzel S, BRAIN STRUCTURE. Cortical folding scales universally with surface area and thickness, not number of neurons. Science. 2015;349(6243):74–7.
21. Wang Y, Leiberg K, Ludwig T, Little B, Necus JH, Winston G, et al. Independent components of human brain morphology. Neuroimage. 2021;226:117546.
22. Bernhardt BC, Bonilha L, Gross DW. Network analysis for a network disorder: the emerging role of graph theory in the study of epilepsy. Epilepsy Behav. 2015;50:162–70.
23. Royer J, Bernhardt BC, Larivière S, Gleichgerricht E, Vorderwülbecke BJ, Vulliémou S, et al. Epilepsy and brain network hubs. Epilepsia. 2022;63(3):537–50.
24. Middlebrooks EH, He X, Grewal SS, Keller SS. Neuroimaging and thalamic connectomics in epilepsy neuromodulation. Epilepsy Res. 2022;182:106916.
25. Girgis F, Miller JP. White matter stimulation for the treatment of epilepsy. Seizure. 2016;37:28–31.
26. Hatton SN, Huynh KH, Bonilha L, Abela E, Alhusaini S, Altmann A, et al. White matter abnormalities across different epilepsy syndromes in adults: an ENIGMA epilepsy study. Brain. 2020;143(8):2454–73.

27. Concha L, Livy DJ, Beaulieu C, Wheatley BM, Gross DW. In vivo diffusion tensor imaging and histopathology of the fimbria-fornix in temporal lobe epilepsy. *J Neurosci*. 2010;30(3):996–1002.
28. McDonald CR, Ahmadi ME, Hagler DJ, Tecoma ES, Iragui VJ, Gharapetian L, et al. Diffusion tensor imaging correlates of memory and language impairments in temporal lobe epilepsy. *Neurology*. 2008;71(23):1869–76.
29. Keller SS, Glenn GR, Weber B, Kreilkamp BAK, Jensen JH, Helpert JA, et al. Preoperative automated fibre quantification predicts postoperative seizure outcome in temporal lobe epilepsy. *Brain J Neurol*. 2017;140(1):68–82.
30. Winston GP, Daga P, White MJ, Micallef C, Miserocchi A, Mancini L, et al. Preventing visual field deficits from neurosurgery. *Neurology*. 2014;83(7):604–11.
31. Costabile JD, Alaswad E, D'Souza S, Thompson JA, Ormond DR. Current applications of diffusion tensor imaging and tractography in intracranial tumor resection. *Front Oncol*. 2019;9(9):426.
32. Gleichgerricht E, Keller SS, Drane DL, Munsell BC, Davis KA, Kaestner E, et al. Temporal lobe epilepsy surgical outcomes can be inferred based on structural connectome hubs: a machine learning study. *Ann Neurol*. 2020;88(5):970–83.
33. McKavanagh A, Kreilkamp BAK, Chen Y, Denby C, Bracewell M, Das K, et al. Altered structural brain networks in refractory and nonrefractory idiopathic generalized epilepsy. *Brain Connect*. 2022;12(6):549–60.
34. Taylor PN, Sinha N, Wang Y, Vos SB, de Tisi J, Miserocchi A, et al. The impact of epilepsy surgery on the structural connectome and its relation to outcome. *NeuroImage Clin*. 2018;18:202–14.
35. Morgan VL, Sainburg LE, Johnson GW, Janson A, Levine KK, Rogers BP, et al. Presurgical temporal lobe epilepsy connectome fingerprint for seizure outcome prediction. *Brain Commun*. 2022;4(3):fcac128.
36. Jeurissen B, Leemans A, Tournier JD, Jones DK, Sijbers J. Investigating the prevalence of complex fiber configurations in white matter tissue with diffusion magnetic resonance imaging. *Hum Brain Mapp*. 2013;34(11):2747–66.
37. Tournier JD, Calamante F, Connelly A. Robust determination of the fibre orientation distribution in diffusion MRI: non-negativity constrained super-resolved spherical deconvolution. *Neuroimage*. 2007;35(4):1459–72.
38. Zhang H, Schneider T, Wheeler-Kingshott CA, Alexander DC. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. *Neuroimage*. 2012;61(4):1000–16.
39. Jensen JH, Helpert JA. MRI quantification of non-gaussian water diffusion by kurtosis analysis. *NMR Biomed*. 2010;23(7):698–710.
40. McKinnon ET, Helpert JA, Jensen JH. Modeling white matter microstructure with fiber ball imaging. *Neuroimage*. 2018;176:11–21.
41. Beniczky S, Aurlien H, Brøgger JC, Hirsch LJ, Schomer DL, Trinka E, et al. Standardized computer-based organized reporting of EEG: SCORE – second version. *Clin Neurophysiol*. 2017;128(11):2334–46.
42. Tatum WO, Rubboli G, Kaplan PW, Mirsafari SM, Radhakrishnan K, Gloss D, et al. Clinical utility of EEG in diagnosing and monitoring epilepsy in adults. *Clin Neurophysiol*. 2018;129(5):1056–82.
43. Jobst BC, Bartolomei F, Diehl B, Frauscher B, Kahane P, Minotti L, et al. Intracranial EEG in the 21st century. *Epilepsy Curr*. 2020;20(4):180–8.
44. Thomas J, Kahane P, Abdallah C, Avigdor T, Zweiphenning WJEM, Chabardes S, et al. A subpopulation of spikes predicts successful epilepsy surgery outcome. *Ann Neurol* [Internet]. 2023;93(3):522–35. <https://doi.org/10.1002/ana.26548>
45. Klimes P, Peter-Derex L, Hall J, Dubeau F, Frauscher B. Spatio-temporal spike dynamics predict surgical outcome in adult focal epilepsy. *Clin Neurophysiol*. 2022;134:88–99.
46. Conrad EC, Revell AY, Greenblatt AS, Gallagher RS, Pattnaik AR, Hartmann N, et al. Spike patterns surrounding sleep and seizures localize the seizure-onset zone in focal epilepsy. *Epilepsia*. 2023;64:754–68. <https://doi.org/10.1111/epi.17482>
47. Bou Assi E, Zerouali Y, Robert M, Lesage F, Pouliot P, Nguyen DK. Large-scale desynchronization during interictal epileptic discharges recorded with intracranial EEG. *Front Neurol*. 2020;23(11):529460.
48. Müller M, Dekkers M, Wiest R, Schindler K, Rummel C. More than spikes: on the added value of non-linear intracranial EEG analysis for surgery planning in temporal lobe epilepsy. *Front Neurol*. 2022;12:741450.
49. Lundstrom BN, Brinkmann BH, Worrell GA. Low frequency novel interictal EEG biomarker for localizing seizures and predicting outcomes. *Brain Commun*. 2021;3(4):fcab231.
50. Stovall T, Hunt B, Glynn S, Stacey WC, Gliske SV. Interictal high frequency background activity as a biomarker of epileptogenic tissue. *Brain Commun*. 2021;3(3):fcab188.
51. Taylor PN, Papasavvas CA, Owen TW, Schroeder GM, Hutchings FE, Chowdhury FA, et al. Normative brain mapping of interictal intracranial EEG to localize epileptogenic tissue. *Brain J Neurol*. 2022;145(3):939–49.
52. Smith G, Stacey WC. The accuracy of quantitative EEG biomarker algorithms depends upon seizure onset dynamics. *Epilepsy Res*. 2021;176:106702.
53. Bernabei JM, Arnold TC, Shah P, Revell A, Ong IZ, Kini LG, et al. Electrocorticography and stereo EEG provide distinct measures of brain connectivity: implications for network models. *Brain Commun*. 2021;3(3):fcab156. <https://doi.org/10.1093/braincomms/fcab156>
54. Jing J, Sun H, Kim JA, Herlopian A, Karakis I, Ng M, et al. Development of expert-level automated detection of epileptiform discharges during electroencephalogram interpretation. *JAMA Neurol*. 2020;77(1):103–8.
55. Fürbass F, Kural MA, Gritsch G, Hartmann M, Kluge T, Beniczky S. An artificial intelligence-based EEG algorithm for detection of epileptiform EEG discharges: validation against the diagnostic gold standard. *Clin Neurophysiol*. 2020;131(6):1174–9.
56. Clarke S, Karoly PJ, Nurse E, Seneviratne U, Taylor J, Knight-Sadler R, et al. Computer-assisted EEG diagnostic review for idiopathic generalized epilepsy. *Epilepsy Behav*. 2021;121:106556.
57. Matos J, Peralta G, Heyse J, Menetre E, Seeck M, van Mierlo P. Diagnosis of epilepsy with functional connectivity in EEG after a suspected first seizure. *Bioeng Basel Switz*. 2022;9(11):690.
58. Thangavel P, Thomas J, Sinha N, Peh WY, Yuvaraj R, Cash SS, et al. Improving automated diagnosis of epilepsy from EEGs beyond IEDs. *J Neural Eng*. 2022;19:066017.
59. Nhu D, Janmohamed M, Antonic-Baker A, Perucca P, O'Brien TJ, Gilligan AK, et al. Deep learning for automated epileptiform

- discharge detection from scalp EEG: a systematic review. *J Neural Eng.* 2022;19(5):051002.
60. Nadalin JK, Eden UT, Han X, Richardson RM, Chu CJ, Kramer MA. Application of a convolutional neural network for fully-automated detection of spike ripples in the scalp electroencephalogram. *J Neurosci Methods.* 2021;360:109239.
 61. Woldman W, Schmidt H, Abela E, Chowdhury FA, Pawley AD, Jewell S, et al. Dynamic network properties of the interictal brain determine whether seizures appear focal or generalised. *Sci Rep.* 2020;10(1):7043.
 62. Varatharajah Y, Joseph B, Brinkmann B, Morita-Sherman M, Fitzgerald Z, Vegh D, et al. Quantitative analysis of visually reviewed normal scalp EEG predicts seizure freedom following anterior temporal lobectomy. *Epilepsia.* 2022;63(7):1630–42.
 63. Abou Jaoude M, Jacobs CS, Sarkis RA, Jing J, Pellerin KR, Cole AJ, et al. Noninvasive detection of hippocampal epileptiform activity on scalp electroencephalogram. *JAMA Neurol.* 2022;79(6):614–22.
 64. Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. *Neuropsychiatr Dis Treat.* 2016;12(12):2605–16.
 65. Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. *Arch Neurol.* 2007;64(11):1595–9.
 66. Lozano AM, Lipsman N, Bergman H, Brown P, Chabardes S, Chang JW, et al. Deep brain stimulation: current challenges and future directions. *Nat Rev Neurol.* 2019;15(3):148–60.
 67. Skarpaas TL, Jarosiewicz B, Morrell MJ. Brain-responsive neurostimulation for epilepsy (RNS® system). *Epilepsy Res.* 2019;153:68–70.
 68. Goyal A, Goetz S, Stanslaski S, Oh Y, Rusheen AE, Klassen B, et al. The development of an implantable deep brain stimulation device with simultaneous chronic electrophysiological recording and stimulation in humans. *Biosens Bioelectron.* 2021;176:112888.
 69. LeCun Y, Bengio Y, Hinton G. Deep learning. *Nature.* 2015;521:436.
 70. Barry W, Arcot Desai S, Tcheng TK, Morrell MJ. A high accuracy electrographic seizure classifier trained using semi-supervised labeling applied to a large spectrogram dataset. *Front Neurosci.* 2021;15:667373.
 71. Lundstrom BN, Van Gompel J, Britton J, Nickels K, Wetjen N, Worrell G, et al. Chronic subthreshold cortical stimulation to treat focal epilepsy. *JAMA Neurol.* 2016;73(11):1370.
 72. Arcot Desai S, Tcheng T, Morrell M. Non-linear embedding methods for identifying similar brain activity in 1 million iEEG records captured from 256 RNS system patients. *Front Big Data.* 2022;5:840508.
 73. Yoo J, Shoaran M. Neural interface systems with on-device computing: machine learning and neuromorphic architectures. *Curr Opin Biotechnol.* 2021;72:95–101.
 74. Zhu B, Shin U, Shoaran M. Closed-loop neural prostheses with on-chip intelligence: a review and a low-latency machine learning model for brain state detection. *IEEE Trans Biomed Circuits Syst.* 2021;15(5):877–97.
 75. Shin U, Somappa L, Ding C, Vyza Y, Zhu B, Trouillet A, et al. A 256-channel 0.227μJ/class versatile brain activity classification and closed-loop neuromodulation SoC with 0.004mm²-1.51 μW/channel fast-settling highly multiplexed mixed-signal front-end. 2022 IEEE International Solid-State Circuits Conference (ISSCC), San Francisco, CA, USA; 2022. p. 338–40.
 76. Shin U, Ding C, Zhu B, Vyza Y, Trouillet A, Revol ECM, et al. NeuralTree: a 256-channel 0.227-μJ/class versatile neural activity classification and closed-loop neuromodulation SoC. *IEEE J Solid-State Circuits.* 2022;57(11):3243–57.
 77. Bin Altaf MA, Zhang C, Yoo J. A 16-channel patient-specific seizure onset and termination detection SoC with impedance-adaptive transcranial electrical stimulator. *IEEE J Solid-State Circuits.* 2015;50(11):2728–40.
 78. Shoaran M, Haghi BA, Taghavi M, Farivar M, Emami-Neyestanek A. Energy-efficient classification for resource-constrained biomedical applications. *IEEE J Emerg Sel Top Circuits Syst.* 2018;8(4):693–707.
 79. Shin U, Ding C, Somappa L, Woods V, Widge AS, Shoaran M. A 16-channel 60μW neural synchrony processor for multi-mode phase-locked neurostimulation. 2022 IEEE Custom Integrated Circuits Conference (CICC), Newport Beach, CA, USA; 2022. p. 1–2.
 80. Shin U, Ding C, Woods V, Widge AS, Shoaran M. A 16-channel low-power neural connectivity extraction and phase-locked deep brain stimulation SoC. *IEEE Solid-State Circuits Letters.* 2023;6:21–24. <https://doi.org/10.1109/LSSC.2023.3238797>
 81. Zhu B, Farivar M, Shoaran M. ResOT: Resource-efficient oblique trees for neural signal classification. *IEEE Trans Biomed Circuits Syst.* 2020;14(4):692–704.
 82. Schindler KA, Rahimi A. A primer on hyperdimensional computing for iEEG seizure detection. *Front Neurol [Internet].* 2021;12:701791.
 83. Kanerva P. Hyperdimensional computing: an introduction to computing in distributed representation with high-dimensional random vectors. *Cogn Comput.* 2009;1(2):139–59.
 84. Rahimi A, Kanerva P, Rabaey JM. A robust and energy-efficient classifier using brain-inspired hyperdimensional computing. In: *Proceedings of the 2016 International Symposium on Low Power Electronics and Design [Internet].* New York, NY, USA: Association for Computing Machinery; 2016. p. 64–9. (ISLPED '16). <https://doi.org/10.1145/2934583.2934624>
 85. Karunaratne G, Le Gallo M, Cherubini G, Benini L, Rahimi A, Sebastian A. In-memory hyperdimensional computing. *Nat Electron.* 2020;3(6):327–37.
 86. Moin A, Zhou A, Rahimi A, Menon A, Benatti S, Alexandrov G, et al. A wearable biosensing system with in-sensor adaptive machine learning for hand gesture recognition. *Nat Electron.* 2020;4(1):54–63.
 87. Rahimi A, Kanerva P, Benini L, Rabaey JM. Efficient biosignal processing using hyperdimensional computing: network templates for combined learning and classification of ExG signals. *Proc IEEE.* 2019;107(1):123–43.
 88. Burrello A, Schindler K, Benini L, Rahimi A. One-shot learning for iEEG seizure detection using end-to-end binary operations: local binary patterns with hyperdimensional computing. 2018 IEEE Biomedical Circuits and Systems Conference (BioCAS), Cleveland, OH, USA; 2018. p. 1–4.
 89. Burrello A, Cavigelli L, Schindler K, Benini L, Rahimi A. Laelaps: an energy-efficient seizure detection algorithm from long-term human iEEG recordings without false alarms. *DATE.* 2019;2019:752–7.
 90. Burrello A, Schindler K, Benini L, Rahimi A. Hyperdimensional computing with local binary patterns: one-shot learning of seizure onset and identification of Ictogenic brain regions

- using short-time iEEG recordings. *IEEE Trans Biomed Eng.* 2020;67(2):601–13.
91. Pale U, Teijeiro T, Atienza D. Multi-centroid hyperdimensional computing approach for epileptic seizure detection. *Front Neurol.* 2022;13:816294.
 92. Karunaratne G, Schmuck M, Le Gallo M, Cherubini G, Benini L, Sebastian A, et al. Robust high-dimensional memory-augmented neural networks. *Nat Commun.* 2021;12(1):2468.
 93. Bassetti CLA, Endres M, Sander A, Crean M, Subramaniam S, Carvalho V, et al. The European academy of neurology brain health strategy: one brain, one life, one approach. *Eur J Neurol.* 2022;29(9):2559–66.
 94. Gribkoff VK, Kaczmarek LK. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. *Neuropharmacology.* 2017;120:11–9.
 95. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov.* 2010;9(3):203–14.
 96. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. *Nat Rev Drug Discov.* 2012;11(3):191–200.
 97. Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. Drug discovery: a jump-start for electroceuticals. *Nature.* 2013;496(7444):159–61.
 98. Sun FT, Morrell MJ. Closed-loop neurostimulation: the clinical experience. *Neurother J Am soc Exp Neurother.* 2014;11(3):553–63.
 99. Borton DA, Dawes HE, Worrell GA, Starr PA, Denison TJ. Developing collaborative platforms to advance neurotechnology and its translation. *Neuron.* 2020;108(2):286–301.
 100. Afshar P, Khambhati A, Stanslaski S, Carlson D, Jensen R, Linde D, et al. A translational platform for prototyping closed-loop neuromodulation systems. *Front Neural Circuits.* 2013;6:117.
 101. Khanna P, Stanslaski S, Xiao Y, Ahrens T, Bourget D, Swann N, et al. Enabling closed-loop neurostimulation research with downloadable firmware upgrades. 2015 IEEE Biomedical Circuits and Systems Conference (BioCAS), Atlanta, GA, USA; 2015. p. 1–6.
 102. Scangos KW, Khambhati AN, Daly PM, Makhoul GS, Sugrue LP, Zamanian H, et al. Closed-loop neuromodulation in an individual with treatment-resistant depression. *Nat Med.* 2021;27(10):1696–700.
 103. Shute JB, Okun MS, Opri E, Molina R, Rossi PJ, Martinez-Ramirez D, et al. Thalamocortical network activity enables chronic tic detection in humans with Tourette syndrome. *NeuroImage Clin.* 2016;12:165–72.
 104. Shivacharan RS, Rolle CE, Barbosa DAN, Cunningham TN, Feng A, Johnson ND, et al. Pilot study of responsive nucleus accumbens deep brain stimulation for loss-of-control eating. *Nat Med.* 2022;28(9):1791–6.
 105. Baud MO, Kleen JK, Mirro EA, Andrechak JC, King-Stephens D, Chang EF, et al. Multi-day rhythms modulate seizure risk in epilepsy. *Nat Commun.* 2018;9(1):88.
 106. Rouse AG, Stanslaski SR, Cong P, Jensen RM, Afshar P, Ullestad D, et al. A Chronic generalized bi-directional brain-machine interface. *J Neural Eng.* 2011;8(3):036018.
 107. Stanslaski S, Herron J, Chouinard T, Bourget D, Isaacson B, Kremen V, et al. A chronically implantable neural coprocessor for investigating the treatment of neurological disorders. *IEEE Trans Biomed Circuits Syst.* 2018;12(6):1230–45.
 108. Malekmohammadi M, Herron J, Velisar A, Blumenfeld Z, Trager MH, Chizeck HJ, et al. Kinematic adaptive Deep Brain Stimulation for Resting Tremor in Parkinson's Disease. *Mov Disord.* 2016;31(3):426–8.
 109. Opri E, Cernera S, Molina R, Eisinger RS, Cagle JN, Almeida L, et al. Chronic embedded cortico-thalamic closed-loop deep brain stimulation for the treatment of essential tremor. *Sci Transl Med.* 2020;12(572):eaay7680.
 110. Kremen V, Brinkmann BH, Kim I, Guragain H, Nasser M, Magee AL, et al. Integrating brain implants with local and distributed computing devices: a next generation epilepsy management system. *IEEE J Transl Eng Health Med.* 2018;6:2500112.
 111. Vansteensel MJ, Pels EGM, Bleichner MG, Branco MP, Denison T, Freudenburg ZV, et al. Fully implanted brain-computer Interface in a locked-In patient with ALS. *N Engl J Med.* 2016;375(21):2060–6.
 112. Mivalt F, Kremen V, Sladky V, Balzekas I, Nejedly P, Gregg NM, et al. Electrical brain stimulation and continuous behavioral state tracking in ambulatory humans. *J Neural Eng.* 2022;19(1):016019. <https://doi.org/10.1088/1741-2552/ac4bfd>
 113. Toth R, Zamora M, Ottaway J, Gillbe T, Martin S, Benjaber M, et al. DyNeuMo Mk-2: an investigational circadian-locked neuromodulator with responsive stimulation for applied chronobiology. *Conf Proc IEEE Int Conf Syst Man Cybern.* 2020;2020:3433–40.
 114. Zamora M, Toth R, Morgante F, Ottaway J, Gillbe T, Martin S, et al. DyNeuMo Mk-1: design and pilot validation of an investigational motion-adaptive neurostimulator with integrated chronotherapy. *Exp Neurol.* 2022;351:113977.
 115. Lázaro-Muñoz G, Yoshor D, Beauchamp MS, Goodman WK, McGuire AL. Continued access to investigational brain implants. *Nat Rev Neurosci.* 2018;19(6):317–8.
 116. Schönau A, Goering S, Versalovic E, Montes N, Brown T, Dasgupta I, et al. Asking questions that matter - question prompt lists as tools for improving the consent process for neurotechnology clinical trials. *Front Hum Neurosci.* 2022;29(16):983226.
 117. Litt B. Engineers drive new directions in translational epilepsy research. *Brain.* 2022;145(11):3725–6.

How to cite this article: Bou Assi E, Schindler K, de Bézenac C, Denison T, Desai S, Keller SS, et al. From basic sciences and engineering to epileptology: A translational approach. *Epilepsia.* 2023;64:S72–S84. <https://doi.org/10.1111/epi.17566>